Sleep Architecture & Cognition in Focal Epilepsy
Part of paid clinical trials in Sacramento, California.
- Sponsor
- University of California, Davis
- Study ID
- NCT05794295
- Status
- Recruiting
Conditions
- Focal Epilepsy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 40 Years
- Healthy Volunteers
- Not accepted
Interventions
- Acoustic Stimulation (AS) — OTHERAcoustic Stimulation will be administered while participants have their sleep monitored.
- SHAM Stimulation — OTHERNo stimulation will be administered while participants have their sleep monitored.
Study Details
Focal Epilepsy (FE) patients and healthy controls will wear an actigraph at home for one week and a home sleep study device at home for one night. Participants will then undergo two nights of testing (at least one week apart) at California Sleep Solutions (CSS) in Sacramento, CA. During the overnight stays, participants will have EEG leads placed and possibly a headband. They will undergo cognitive testing before they go to sleep and again in the morning. During one night of testing, sounds will be played in the room (acoustic stimulation). The sounds should not wake the participants.
Key Dates
- Start date
- Jan 24, 2025
- Status verified
- Jul 2025
- Primary completion
- Dec 1, 2026
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Active Comparator: Acoustic Stimulation (AS)Participants in this arm will be exposed to acoustic stimulation while they sleep during a night of monitoring.
- Sham Comparator: SHAM StimulationParticipants in this arm will not be exposed to any stimulation while they have their sleep monitored for one night.
Primary Outcome Measure
Stanford Sleepiness Scale [ Time Frame: participant completes over one week post EMU stay ]
Central Contacts
- Temitayo Oyegbile-Chidi, MD916-318-3111
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UC Davis | Sacramento | California | 95817 | Temitayo Oyegbile-Chidi, MD 916-318-3111 |
Find similar trials in Sacramento, CA
By research site
Related Studies
- An Open-label Study of XEN1101 in EpilepsyPHASE3 · Enrolling By Invitation · Xenon Pharmaceuticals Inc. · Phoenix, Arizona
- A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyPHASE2/PHASE3 · Recruiting · Biohaven Therapeutics Ltd. · Phoenix, Arizona
- Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyPHASE2/PHASE3 · Recruiting · Biohaven Therapeutics Ltd. · Birmingham, Alabama
- Long-term Safety and Tolerability of BHV-7000PHASE2 · Enrolling By Invitation · Biohaven Therapeutics Ltd. · Birmingham, Alabama